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Withdrawal of inhaled corticosteroids is known to worsen disease control in bronchial asthma but similar data are 
lacking in chronic obstructive pulmonary disease (COPD). We hypothesized that clinical exacerbations requiring 
treatment would occur more often in patients whose inhaled corticosteroids were stopped than in other patients not 
treated with these agents. We studied 272 patients of mean age 65 (SD 0.8) years, mean FEV, 42.8 (SD 12.6)% 
predicted, entering the run-in phase of the Inhaled Steroids in Obstructive Lung Disease (ISOLDE) trial. All had 
been clinically stable for at least 6 weeks and there were no differences in the degree of bronchodilator reversibility, 
baseline lung function or pack-years of smoking between the 160 patients receiving inhaled corticosteroids and those 
not so treated. Inhaled corticosteroids were withdrawn in the first week of the study and during the remaining 7 
weeks of the study 38% of those previously treated with these drugs had an exacerbation compared to 6% of the 
chronically untreated group. Patients receiving inhaled corticosteroids reported a longer duration of symptoms but 
neither this or any other recorded variable predicted the risk of exacerbation. These data suggest that abrupt 
withdrawal of inhaled corticosteroids should be monitored carefully even in patients with apparently irreversible 
COPD. 
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Introduction 
Inhaled corticosteroids are recognized as being the corner- 
stone of the management of chronic bronchial asthma (1,2). 
Placebo-controlled trials in stable asthma have shown that 
the FEV,, symptom scores and bronchial reactivity all 
improve significantly with regular inhaled corticosteroid 
treatment (3). Conversely, withdrawal of oral corticoster- 
oids in unstable asthma (4) and even in stable asthma will 
produce symptomatic and objective relapse at variable 
times after treatment cessation (S-7). 
The position in chronic obstructive pulmonary disease 
(COPD) is much less certain. Short courses of oral corti- 
costeroids can produce significant increases in FEV, in 
approximately 20% of patients with COPD (g-10). One 
open long-term follow-up study has suggested that mor- 
Received 18 June 1998 and accepted in revised form 16 October 
1998. 
Correspondence should be addressed to: Professor P. M. A. 
Calverley, University Clinical Departments, Aintree NHS Trust, 
Longmoor Lane, Liverpool L9 7AL, U.K. 
0954-6111/99/030161+06 $12.00/O 
.“_. .
tality in COPD is reduced in those patients showing an 
initial improvement in spirometry after oral corticosteroids 
(11). Inhaled beclomethasone in moderate to high dosage 
can produce similar short-term effects to oral prednisolone 
(12) whilst other studies suggest that these improvements 
can be sustained with regular therapy (13,14). However 
there are no data about the effect of inhaled corticosteroid 
withdrawal in COPD patients. All the studies described 
above have limitations of design and/or statistical power. 
To resolve these problems, two prospective studies of 
inhaled corticosteroids in COPD, EUROSCOP (15) and 
ISOLDE (16), have been established and are due to report 
soon. The Inhaled Steroids in Obstructive Lung Disease 
(ISOLDE) study is a multi-centre investigation based in the 
U.K. where the empirical use of inhaled corticosteroids in 
COPD is widespread. Patients already established on this 
treatment can enter the study if they are shown to be stable 
off corticosteroid therapy. We hypothesized that a percent- 
age of the patients who had received inhaled corticosteroids 
would have benefited from this chronic anti-inflammatory 
treatment and would show an increased exacerbation rate 
when it was withdrawn. The run-in phase of ISOLDE 
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allowed us to observe whether this was the case and 
determine whether there were any simple factors which 
id&&ed patients likely to deteriorate. 
Methods 
Patients were recruited for this study from the hospital 
outpatient departments and affiliated general practices of 
six of the centres participating within the ISOLDE trial. 
Each patient had a clinical history of COPD (17), was aged 
between 40 and 75 years and had evidence of significant 
airflow obstruction with an FEV, greater than 0.8 1 but less 
than 70% of predicted values 30 min after receiving 400 mcg 
salbutamol from a metered dose inhaler via a volumatic 
spacer. Their FEV,/FVC ratio was less than 75% and none 
showed more than a 10% of predicted FEV, improvement 
from baseline after the inhaled salbutamol. Patients with 
concurrent life-threatening illnesses or clinical features sug- 
gestive of bronchial asthma or a previous physician diag- 
nosis of asthma were excluded and all had been clinically 
stable for at least 3 months before entry. All patients were 
receiving symptomatic bronchodilator treatment with 
p-agonists or anticholinergics and those receiving methylx- 
anthines were allowed to continue these drugs. Patients 
taking regular oral prednisolone were not eligible, although 
treatment with oral prednisolone for acute exacerbations in 
the preceding year did not exclude entry. Informed consent 
for the study was obtained from all patients and the study 
protocol was approved by the local ethical committees of 
the participating centres prior to the study. 
Patients attended on three occasions. At the first visit 
they completed an MRC respiratory questionnaire (18) 
from which demographic details, disease duration and the 
smoking history were extracted. Smoking exposure was 
expressed as pack years with 20 g of tobacco being consid- 
ered equivalent to 1 packet of commercial cigarettes in 
those who used hand-rolled tobacco. Spirometry was per- 
formed using a computerized rolling seal spirometer 
(Sensormedics type 922, Amsterdam) the patient being 
instructed not to take any oral or inhaled bronchodilators 
for 6 h before the study. The FEV, and FVC were recorded 
from the three best traces which were within 10% of each 
other, particular care being taken to ensure the reproduc- 
ibility of the FEV, and FVC manoeuvres (19). After the 
initial spirometry patients were given 400 mcg salbutamol 
by metered dose inhaler through a volumatic spacer and 
the spirometry was repeated 30 min later. Reversibility 
was expressed according to the equation: FEV, post 
salbutamol - FEV, pre-salbutamol/predicted FEV, x 100. 
The predicted values were those of the European Coal and 
Steel Community (ECSC) (20). Patients were considered 
eligible if the change in FEV, after bronchodilator was less 
than 10% of their predicted baseline FEV,. The transfer 
factor for carbon monoxide (2X0) and the transfer co- 
efficients (KCO) were measured using the single breath 
method in all patients. Plasma cortisols were taken between 
0800h and lOOOh to seek evidence of prior adrenal suppres- 
sion whilst plasma IgE and eosinophil counts were taken as 
potential markers of allergic status. A history of the inhaled 
and oral corticosteroid exposure during the previous 
history was also obtained. 
Those patients who had received inhaled corticosteroids 
were told to withdraw these at their own discretion during 
the next 7 days and given an appointment to return. 
Patients were reviewed at 4 and 8 weeks after the initial visit 
for evidence of clinical stability. Our predefined definition 
of an exacerbation of COPD was an episode of ‘increased 
shortness of breath and/or sputum production requiring 
treatment with antibiotics and/or prednisolone’. Where 
treatment was required it was instituted by a hospital 
physician familiar with the study protocol or, less 
frequently, by the patient’s own general practitioner. 
Data are expressed as mean (SD) unless otherwise stated. 
The chi-squared test was used to compare frequencies of 
exacerbations and duration of disease, and the Student’s 
t-test for continuous data with a normal distribution (age, 
plasma cortisol and serum IgE). 
The Mann-Whitney U-test was used where data were not 
normally distributed (pack-years cigarette smoking and the 
dose of inhaled and oral steroids). Due to the multiple 
comparisons performed in the study the value of P was 
corrected using the equation described by Bonferroni (21): 
P .,,=P x k, 
where k is the number of analyses undertaken (26 analyses 
in this study). The results were considered significant if P,,,, 
was less than 0.05. 
Results 
All patients entering the run-in from the six participating 
centres were included; a total of 272 patients. Most were 
men (72%) with a mean FEV, of 42.1 (12+)% predicted 
and limited bronchodilator reversibility (4.2% predicted 
increase from baseline) compatible with COPD. There were 
no inter-centre differences in the baseline characteristics of 
the patients. 
PATIENTS CHARACTERIZED BY TREATMENT 
AT STUDY ENTRY 
One hundred and sixty patients (59%) were receiving regu- 
lar inhaled corticosteroids (Group 1) (median daily dose 
800 mcg, range 50-2400) as either beclomethosone dipropi- 
onate or budesonide when enrolled. These are compared to 
the remaining 112 patients (Group 2) in Table 1. There were 
no significant differences in any characteristics save that 
patients receiving inhaled corticosteroids (Group 1) 
reported a longer duration of symptoms than those not so 
treated (Group 2) (odds ratio 3.13, 95% CI 1.84-5.32; 
PCO.001). 
PRIOR ORAL CORTICOSTEROID USE 
Seventy-six patients had had at least one exacerbation 
requiring oral corticosteroids in the year before study entry. 
Of these 56 were receiving inhaled corticosteroids, i.e. 35% 
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TABLE 1. Demographic data for patients who were and were not on inhaled steroids 
Patients on 
inhaled steroids 
(n= 160) 
Patients not on 
inhaled steroids 
(n=112) P corr 
Median age (range) 
Sex (M:F) 
Duration of COPD 
<l yr 
l-5 yr 
6-10 yr 
>lO yr 
Smoking (pack years) median (range) 
Mean baseline FEV, (% predicted) (SD) 
Percentage reversibility of FEV, to salbutamol mean (SD) 
fiC0 (mmol min - ’ kPa - ‘) 
KC0 (mmol min - ’ kPa ~ ’ 1 - ‘) 
IgE (mg I- ‘) median (range) 
Eosinophil count x lo9 l- i median (range) 
66 (41-75) years 66 (4675) years n.s. 
119:42 80:35 n.s. 
8 (4%) 19 (16%) <O.OOl 
46 (29%) 48 (42%) 
38 (24%) 17 (15%) 
69 (43%) 31 (27%) 
45 (4-227) 43 (2-183) us. 
41.4 (12.4) 44.6 (13.2) us. 
4.3 (2.3) 4.1 (2.7) n.s. 
4.95 (1.8) 5.09 (1.8 ) n.s. 
1.05 (0.43) 1.22 (1.35) n.s. 
72 (o-1200) 58 (51200) n.s. 
0.11 (O-0.45) 0.12 (O-0.55) us. 
TABLE 2. Demographic data, respiratory function tests and baseline blood tests in study groups. Patients who had 
exacerbations were more likely to be on inhaled steroids than patients who did not (odds ratio 9.5, C.I. 4.0-23.8, P<O.OOl) 
Age, median (SEM) 
Sex (M:F) 
Pack year cigarette smoking, median (range) 
Post-salbutamol FEV, mean % predicted (SD) 
Reversibility of FEV, to salbutamol (%), mean (SD) 
RCO (mm01 min - i kPa - ‘) 
KC0 (mmol min - ’ kPa - ’ 1 - ‘) 
Baseline plasma cortisol (nmol l- ‘) 
No exacerbations 
Not on IS On IS 
(105) (100) 
64 (0.7) 64 (0.7) 
73~32 72:28 
50 (10-183) 40 (7-127) 
49 (12) 45 (12) 
4.4 (3.1) 4.1 (30) 
5.1 (1.9) 5.0 (1.9) 
1.0 (0.5) 1.0 (0.4) 
363 (146) 341 (126) 
Exacerbations 
Not on IS On IS 
(7) (60) 
66 (4) 66 (0.8) 
6:l 45:lS 
45 (30-60) 47 (4-153) 
41 (4) 46 (12) 
4.2 (3.1) 4.3 (3.2) 
5.4 (2.5) 4.8 (2.1) 
1.2 (0.8) 1.1 (0.6) 
370 (98) 339 (46) 
of Group 1 patients. This was a significantly higher pro- 
portion (PcO.05) than the 20 patients with a history of oral 
steroid use in Group 2. However, the average annual dose 
of prednisolone was higher in the Group 2 patients who had 
taken this compared with those treated in Group 1 (411 w 
244 mg per year; PcO.02) suggesting that they had required 
corticosteroids for longer periods or received treatments 
more frequently. 
EXACERBATIONS OF COPD DURING 
FOLLOW-UP 
Sixty-seven (25%) patients had at least one exacerbation of 
COPD requiring treatment during the g-week study period 
(Table 2). In 55 (82%) the exacerbation occurred during the 
1st month of observation (median 20 days). Ninety per cent 
of patients with an exacerbation had received inhaled 
corticosteroids previously, compared with 48% of those not 
exacerbating (odds ratio 9.5, 95% CI 4.0-23.3, P<O.OOl). 
Although the daily dose of inhaled corticosteroids in the 
year before study was greater in the corticosteroid-treated 
patients who had an exacerbation (mean 945, median 
800 mcg day- ‘) compared with similar patients who did 
not (mean 712, median 534) these difference were not 
statistically significant. There was no correlation between 
the total dose of inhaled or oral corticosteroids used in the 
year before study and the time between stopping the 
corticosteroids in the first exacerbation. There were no 
differences in the baseline characteristics listed above, nor in 
markers of a potential asthmatic tendency between patients 
who had received inhaled corticosteroids and exacerbated 
and those who did not. 
Discussion 
Chronic obstructive pulmonary disease is an important 
cause of mortality and morbidity in the U.K. and elsewhere 
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throughout Europe (22). There is increasing evidence that 
airway inflammation is a frequent finding in COPD (23), 
perhaps associated with a different pattern of lymphocyte 
activation than in asthma (24), and can respond physiologi- 
cally to oral corticosteroids, especially when the eosinophil 
cationic protein (ECP) levels in bronchoalveolar lavage are 
high (25). Regular treatment with inhaled corticosteroids 
may modify the rate of decline of pre-bronchodilator FEV, 
(14) but they have less impressive effects than lung function 
decline in mild disease when patients continue to smoke, as 
suggested by preliminary analysis of the EUROSCOP data. 
This is the first report to observe that withdrawal of inhaled 
corticosteroids leads to a clinically significant deterioration 
more often than would be expected among clinically and 
physiologically similar patients who have not received this 
treatment. 
The trial design we have used has a number of limita- 
tions. The principal purpose of the ISOLDE study is to 
demonstrate in a double-blind placebo-controlled fashion 
that regular treatment with inhaled fluticasone propionate 
reduces the rate of decline in lung function and improves 
the quality of life of patients with stable COPD. To draw 
this conclusion it is important that the baseline value of 
lung function be representative of the patient’s usual value. 
For the purpose of this report it would have been better 
to randomize patients to treatment with active or placebo 
inhaled corticosteroids and our inability to do so restricts 
the conclusions we can draw. However, recruitment for 
such a large multi-centre study is difficult and the inclusion 
of a protracted run-in period might have compromised the 
main purpose of the study. Since this is the first large scale 
COPD study in which patients had their prior inhaled 
steroids withdrawn we felt that the large number of subjects 
involved would go some way to compensate for some of 
these design difficulties. The investigators who collected the 
data and the patients themselves were unaware of the 
hypothesis being tested or the reasons for the additional 
data being collected. Thus we think it unlikely that the 
differences between the two groups arose by chance. It is 
possible that patients used to receiving inhaled corticoster- 
oids might be more anxious when they were withdrawn but 
the ,great majority of patients in this study, and in our 
clinical practice, do not attribute specific benefits to using 
their inhaled corticosteroids and, if anything, are more 
concerned about the possibility of side-effects, making this 
placebo response unlikely. 
There is no universally agreed definition of an exacer- 
bation of COPD and the role of bacterial infection is 
unclear and often difficult to establish (26). In the U.K. 
prescription of oral corticosteroids is reversed for clinically 
more severe episodes associated with breathlessness. Thus, 
we felt that institution of a course of corticosteroids was 
likely to represent a clinically significant event. Data about 
the occurrence of exacerbations of COPD are remarkably 
scarce (27) but two recent studies give some insight into 
this. In one a group of moderate to severe COPD patients 
(mean FEV, 1.6 l), most of whom received inhaled corti- 
costeroids, reported an average of 1.5 exacerbations per 
year, although an equivalent number of unreported epi- 
sodes occur (28). In the second, 139 patients (mean FEV, 
1.52 1) with a past history of exacerbations experience 111 
exacerbations in 6 months, an annual rate of 1.6 episodes 
per year (29). Assuming an equivalent rate in our patients, 
one-quarter of those stopping inhaled corticosteroids might 
experience exacerbation, whilst one-third did so. The low 
rate in those not receiving corticosteroids may be a chance 
occurrence and would require a longer follow-up period to 
explain. 
Treatment of exacerbations before entry was not stand- 
ardized and we would have liked information about the 
number of exacerbations treated by antibiotics alone. There 
were more individuals treated with oral corticosteroids in 
the preceding year among Group 1 patients, but those who 
had exacerbated in Group 2 before study entry had 
required oral therapy more often or for longer. Thus, the 
chances of an exacerbation occurring in a given group were 
broadly equivalent. 
Although not the ideal control population, the patients 
who had not received inhaled corticosteroids appeared to 
be physiologically identical and to have similar degrees of 
reduction in their KCO. There were no differences in other 
medication between the groups and all of the patients had 
been stable on their previous medication for at least 3 
months. 
Given the original homogeneity of the population we 
believe that the difference in exacerbation rates is probably 
due to corticosteroid withdrawal, even allowing for the 
limitations of our study design. It is possible that the Group 
1 patients included a large number of ‘hidden asthmatics’, 
but this seems unlikely given the high tobacco intake, the 
very limited bronchodilator response and the paucity of 
allergic markers. 
We could not predict which patients would subsequently 
exacerbate. Similarly, when similar patients were studied 
previously no combination of clinical or laboratory features 
predicted a bronchodilator response to a trial of oral 
corticosteroids (10). Data such as these suggest that the 
initial clinical picture is a poor guide to either the benefits of 
corticosteroid treatment or the risk of relapse on their 
withdrawal. In this study we have used exacerbations of 
COPD as our principal endpoint and although there is no 
widely accepted definition, the one used proved to be easy 
to apply in the clinical setting and is similar to that 
employed in longer-term studies of inhaled corticosteroids 
in asthma (30). Its sensitivity in detecting clinically signifi- 
cant changes in these patients makes us believe that it 
should be incorporated as an appropriate study end-point 
in future investigations. 
The reason for these exacerbations among the 
corticosteroid-using patients is still unclear. It seems 
unlikely that the initial clinical assessment was so precise as 
to pick out those patients showing a corticosteroid response 
compared with those who do not (see above). Given the 
recent information about inflammatory changes in the 
airways of COPD patients it seems possible that chronic 
suppression of lymphocytes and eosinophils by inhaled 
corticosteroids might lead to a rebound increase in these 
cells when the treatment was withdrawn and that this 
may help precipitate an increase in symptoms requiring 
treatment. Previous studies have suggested that sputum 
eosinophilia is a potential marker for a favourable cortico- 
steroid response in COPD, whilst acute eosinophilia occurs 
during inflammatory exacerbations of mild to moderate 
COPD as demonstrated on biopsy studies (31). This 
explanation must remain speculative until more direct 
evidence is obtained of the effects of corticosteroids on the 
histology of the airways in COPD and its relationship, if 
any, to their effects on the natural history of the disease. 
These data do have practical implications. Our findings 
cannot give insight into whether long-term inhaled corticos- 
teroids confer benefit. However, many research protocols 
involve the reduction or stopping of medications before 
study entry. Our data suggest that this may lead to early 
exacerbation if inhaled corticosteroids are rapidly with- 
drawn in stable COPD. Similarly, the controversy about the 
clinical role of inhaled corticosteroids in COPD means that 
different physicians may offer differing advice to patients 
about whether they should continue their therapy and the 
patients themselves may decide to discontinue treatment 
which is not giving them immediate benefit. Given the 
limitations of our study design, further randomized studies 
will be needed to confirm our findings and define the most 
appropriate way to stop inhaled corticosteroid treatment in 
COPD. In the meantime, clinicians should be aware of the 
risk of an exacerbation developing within a few weeks of 
stopping this treatment. 
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